Revance Therapeutics

Revance Therapeutics is a biotechnology company that develops and commercializes products and treatments for dermatological diseases. The Company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based on a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance’s initial focus is on developing daxibotulinumtoxinA, the Company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The Company’s lead drug candidate, DaxibotulinumtoxinA for Injection, is currently in development for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis, and has the potential to be the first long-acting neurotoxin. 

Company Growth (employees)
Newark, US
Size (employees)
131 (est)+11%
Revance Therapeutics was founded in 2002 and is headquartered in Newark, US

Revance Therapeutics Office Locations

Revance Therapeutics has an office in Newark
Newark, US (HQ)
7555 Gateway Blvd

Revance Therapeutics Financials and Metrics

Revance Therapeutics Financials

Revance Therapeutics's revenue was reported to be $300 k in FY, 2016

Revenue (Q2, 2017)

75 k

Net income (Q2, 2017)

(26.9 m)

EBIT (Q2, 2017)

(26.8 m)

Market capitalization (13-Dec-2017)

1 b

Cash (30-Jun-2017)

53.7 m
Revance Therapeutics's current market capitalization is $1 b.
USDFY, 2014FY, 2015FY, 2016


383 k300 k300 k

Revenue growth, %


R&D expense

47.5 m50.4 m

General and administrative expense

25.1 m29.1 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


158 k75 k75 k75 k75 k75 k75 k75 k75 k75 k75 k

R&D expense

7.6 m8.1 m8.6 m9.3 m10.3 m13 m12.4 m15.2 m10.3 m19.4 m18.3 m

General and administrative expense

6 m6.4 m5.8 m7.5 m7 m7.5 m7.8 m8.6 m

Operating expense total

11.6 m13 m13.9 m15.3 m16.7 m18.8 m19.8 m24.2 m17.8 m27.2 m26.9 m
USDFY, 2014FY, 2015FY, 2016


171 m201.6 m63.5 m

Accounts Receivable

155.5 m


1.6 m1.6 m7.2 m

Current Assets

172.7 m254 m192.7 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


87.9 m203.3 m187.5 m153.7 m96.4 m90.5 m40.8 m52.7 m130.5 m38.2 m53.7 m

Current Assets

91.2 m206.6 m190.9 m155.7 m137.3 m143.5 m238.5 m218.6 m208.7 m197.5 m174.4 m


15.2 m16.3 m17.4 m19.4 m19.1 m19.3 m19.7 m17.7 m17.4 m11.2 m11.3 m

Total Assets

106.9 m223.3 m208.9 m175.7 m171.2 m165.5 m259 m237 m226.9 m209.5 m187.1 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(62.9 m)(73.5 m)(89.3 m)

Depreciation and Amortization

2.1 m2 m1.4 m


(999 k)(192 k)(5.6 m)

Accounts Payable

(3.4 m)(692 k)953 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(32.2 m)(51.4 m)(19.9 m)(44.5 m)(62.5 m)(27.2 m)

Depreciation and Amortization

1.1 m1.6 m344 k699 k1.1 m

Accounts Payable

2.7 m2.7 m2.1 m(938 k)(477 k)552 k279 k200 k5.6 m

Cash From Operating Activities

(25.5 m)(39.2 m)(15.7 m)(32 m)(46.4 m)
Y, 2017

Financial Leverage

1.2 x
Show all financial metrics

Revance Therapeutics Market Value History

Revance Therapeutics's Web-traffic and Trends

Revance Therapeutics Company Life and Culture

You may also be interested in